Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer

Citations Over TimeTop 22% of 2018 papers

Abstract

Cancer cells overexpress a diversity of anti-apoptotic BCL-2 family proteins, such as BCL-2, MCL-1, and BFL-1/A1, to enforce cellular immortality. Thus, intensive drug development efforts have focused on targeting this class of oncogenic proteins to overcome treatment resistance. Whereas a selective BCL-2 inhibitor has been FDA approved and several small molecule inhibitors of MCL-1 have recently entered phase I clinical testing, BFL-1/A1 remains undrugged. Here, we developed a series of stapled peptide design principles to engineer a functionally selective and cell-permeable BFL-1/A1 inhibitor that is specifically cytotoxic to BFL-1/A1-dependent human cancer cells. Because cancers harbor a diversity of resistance mechanisms and typically require multi-agent treatment, we further investigated BFL-1/A1 co-dependencies by mining a genome-scale CRISPR-Cas9 screen. We identified ataxia-telangiectasia-mutated (ATM) kinase as a BFL-1/A1 co-dependency in acute myeloid leukemia (AML), which informed the validation of BFL-1/A1 and ATM inhibitor co-treatment as a synergistic approach to subverting apoptotic resistance in cancer.

Related Papers

• → CRISPR-repressed toxin–antitoxin provides herd immunity against anti-CRISPR elements(2024)17 cited
• → The advancements, challenges, and future implications of the CRISPR/Cas9 system in swine research(2021)23 cited
• → Using CRISPR/Cas9 Technology for Manipulating Cell Death Regulators(2016)25 cited
• → The emerging role of CRISPR-Cas9 in molecular oncology(2017)1 cited
• → Brief Introduction to CRISPR Cas9(2022)